Rodman & Renshaw Outperform On Keryx Biopharmaceuticals

Rodman & Renshaw is out with a research report on Keryx Biopharmaceuticals KERX and it has an Outperform rating and a $8 price target on shares. In a note to clients, Rodman & Renshaw writes, "We are reiterating our Market Outperform / Speculative Risk rating and our target price of $8 based on a discounted 2015 revenues and earnings multiples analysis. The completion of the review by the DSMB highlights the safety of perifosine in combination with capecitabine. The perifosine Phase 2 colorectal cancer data provide a strong rationale for a positive outcome of the Phase 3 trial. Perifosine is also in a Phase 3 trial for the treatment of relapsed/refractory multiple myeloma. Finally, Keryx is conducting a Phase 3 trial to evaluate the potential for the phosphate binder Zerenex to lower phosphate in ESRD patients on dialysis. In our opinion, Keryx represents an undervalued opportunity for investors seeking a triple “Phase 3 pure-play” in myeloma, colorectal cancer and hyperphosphatemia combined with peak total revenues of approximately $500 MM, and with multiple partnering opportunities." At last check, shares of KERX were up 2 cents to $4.90.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsBiotechnologyHealth CareRodman & Renshaw
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!